Military Medical Research and Development

 

Through the support of basic, applied, and advanced biomedical research: (1) to transform health care for Service Members and the American public through innovative and impactful research; (2) to investigate medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense, clinical and rehabilitative medicine, blast injury and regenerative medicine; and (3) to fund novel approaches to biomedical research in response to the expressed needs of Congress.

Active 12.420 Department of The Army, Department of Defense B - Project Grants Fiscal Year 2016 Funding is supporting a broad range of medical solutions, including: (1) advancement of research in psychological health, sensory systems, pain management, and regenerative medicine, (2) addressing critical gaps in medical training/simulation, infection and wound healing, acute trauma care, operational readiness, radiation health effects, and rehabilitation, (3) development and clinical testing of immunotherapies and vaccines to treat or prevent cancer and infectious diseases, (4) discovery of new treatments for prevalent conditions such as diabetes and autism and for trauma-related conditions such as tissue, orthopaedic, and spinal cord injuries, and (5) development of novel imaging and diagnostic technologies for traumatic injuries, cancer, and Alzheimer's disease. Funding is supporting a broad range of medical solutions, including: (1) advancement of research in psychological health, sensory systems, pain management, and regenerative medicine, (2) addressing critical gaps in medical training/simulation, infection and wound healing, acute trauma care, operational readiness, radiation health effects, and rehabilitation, (3) development and clinical testing of immunotherapies and vaccines to treat or prevent cancer and infectious diseases, (4) discovery of new treatments for prevalent conditions such as diabetes and autism and for trauma-related conditions such as tissue, orthopaedic, and spinal cord injuries, and (5) development of novel imaging and diagnostic technologies for traumatic injuries, cancer, and Alzheimer's disease.
Fiscal Year 2019 Information on past projects funded under this Assistance Listing may be found on the Defense Technical Information Center’s website at: https://dodgrantawards.dtic.mil/grants/#/home. Click on “Advanced Search” then select the “Medical Research & Material Command/Congressionally Directed Medical Research Programs” under “DoD Awarding Agency
Fiscal Year 2020 The Congressionally Directed Medical Research Programs (CDMRP) is a global funding organization that fosters novel approaches to biomedical research in response to the expressed needs of its stakeholders–the American public, the military, and Congress. CDMRP originated in 1992 when Congress first appropriated funds to the Department of Defense (DOD), specifically for breast cancer research. Since that time, Congress has added additional research programs and topics. CDMRP now manages individual research programs focused on military medical research, cancer research, and other disease-, disorder-, and injury-specific research. All the programs managed by CDMRP share the common goal of advancing paradigm-shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. CDMRP strives to transform healthcare for Service members and the American public by funding innovative and impactful research. CDMRP oversees the investment of congressionally directed dollars to fund groundbreaking, high-impact, high-risk, high-reward, meritorious research that targets critical research gaps. CDMRP also provides management support of intramural and extramural military medical research. CDMRP is located under the US Army Futures Command and within US Army Medical Research and Development Command (USAMRDC). Since it first originated in fiscal year 1992 (FY92), CDMRP has been responsible for managing more than $15.94 billion (B) in funding targeted for congressionally directed research areas/topics.
Fiscal Year 2021 Since the first program appropriation in 1992, Congressionally-Directed Medical Research Program (CDMRP) funded research has significantly advanced knowledge, technologies, and products that are saving and improving lives: • U.S. Food and Drug Administration (FDA)-approved drugs and therapeutic strategies • Diagnostic and prognostic biomarkers/tests • Novel approaches to prevention and treatment • Imaging technologies for clinical use • New standards of care and clinical practice • Biorepositories with clinical samples and data Additional research accomplishment highlights for each CDMRP program can be found at: https://cdmrp.army.mil/highlights/default Highlights are available in individual program materials as well as the CDMRP Annual Report published each year: https://cdmrp.army.mil/pubs/annreports/annual_reports
Fiscal Year 2023 In 2022, the Congressionally Directed Medical Research Program (CDMRP) managed 35 FY22 Congressional Special Interest programs. The CDMRP also provided program and award management support to other core Department of Defense (DOD) medical research programs. The CDRMP invests in groundbreaking research across the full spectrum of research and development, including basic, translational, and clinical research. By strategically funding high-risk, high-reward research projects that other agencies may not be willing to fund, the CDMRP addresses critical research gaps. CDMRP funded research benefits not only military members, military retirees, and family members, but the civilian population as well. The CDMRP underwent a comprehensive review by the Comptroller General, as directed in the FY21 Defense Appropriations Act (HR 133). The Government Accountability Office favorably assessed the CDMRP and provided entirely positive findings, listing no deficiencies and providing no recommendations for change. 10 U.S.C. 4001 Federal, State, and local governments; public, State, and private institutions of higher education, Federally Recognized Indian Tribal government, U.S. territory or possession, small business, profit organization, private nonprofit institution/organization, quasi-public nonprofit institution/organization, other private institution/organizations, and Native American organizations. Awards are not made to individuals. Federal, State, and local governments; public, State, and private institutions of higher education, Federally Recognized Indian Tribal government, U.S. territory or possession, small business, profit organization, private nonprofit institution/organization, quasi-public nonprofit institution/organization, other private institution/organizations, and Native American organizations. Recipient eligibility is contingent upon submission of certifications and representations required by Federal statutes and executive orders. Applicants must have a current registration in the System for Award Management (www.sam.gov) and furnish evidence of financial stability and managerial capability. Specific notices of funding opportunity require additional research-related and administrative documentation, and may also require safety, environmental, and other regulatory documentation prior to the award of any grant or cooperative agreement. Health/Medical Grant and cooperative agreement awards provide funds to develop science and technology capabilities in specific areas of interest identified in each funding opportunity announcement. Notices of funding opportunity may be called Broad Agency Announcements or Program Announcements. Recipients must strictly conform to all applicable Federal, Department of Defense (DoD), Defense Health Agency (DHA), and U.S. Army Medical Research and Development Command (USAMRDC) requirements for conducting research, including regulatory requirements involving human subjects, human anatomical substances, human cadavers, and animals. Preapplication coordination is required. Preapplication coordination is required. Each notice of funding opportunity specifies applicable pre-application requirements. Notices of funding opportunity typically require the applicant’s Principal Investigator to submit a pre-application through the Electronic Biomedical Research Application Portal (eBRAP, available at https://eBRAP.org/). Pre-applications are screened for military relevance and technical merit against criteria stated in each notice of funding opportunity. Following pre-application screening, the applicant’s Authorized Organization Representative and Principal Investigator will be notified regarding whether the applicant is invited to submit a full application. Environmental impact information is not required for this program. This program is excluded from coverage under E.O. 12372. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. All extramural applications for assistance under this program must be submitted through the Grants.gov website (available at www.grants.gov). Applicants can find specific application procedures, including necessary forms and instructions for application submission, in each notice of funding opportunity. Notices of funding opportunity are available at Grants.gov by searching Assistance Listing Number 12.420 on the "Search Grants" tab. All invited applications are evaluated by USAMRDC scientists, other Federal agency representatives, outside scientists with diverse expertise, clinicians, consumers, or combinations thereof, using a two-tier review process. The first tier is a peer review of applications against criteria stated in each notice of funding opportunity to determine technical merit. The second tier is a programmatic review that makes recommendations for funding based on technical merit, military relevance, the specific intent of the funding opportunity, and any other criteria specified in the notice of funding opportunity. The best-scoring applications from the first tier of review are not automatically recommended for funding. Award amount will be negotiated for those applications recommended for funding. Awards depend upon the availability of funding and priorities which USAMRDC determines to exist at the time of award. Only the Grants Officer has the authority to issue awards and obligate funds on behalf of the Federal government. Several Program Announcements are issued through the year for this Assistance Listing. See the individual Program Announcement or Broad Agency Announcement for deadlines associated with that particular program. Current Program Announcements and Broad Agency Announcements are available at: https://cdmrp.army.mil/funding/prgdefault. Contact the headquarters or regional location, as appropriate for application deadlines Pre-applications are normally reviewed within 30 to 60 days from submission deadline or, if no deadline, within 120 days from date of receipt. Full applications are usually reviewed and notifications whether or not applications have been recommended for funding issued within 180 days from submission deadline or, if no deadline, from date of receipt. Awards are normally made within 9-12 months from funding notification. If an application is not recommended for funding and the Principal Investigator believes that a factual or procedural error was made by the reviewers, (s)he can submit an inquiry. Each notice of funding opportunity will include instructions for submitting an inquiry and the timeframe for submission. An award may be extended one time up to 12 months with no additional funds. Additional extensions may be considered. Follow on awards are treated as new awards. Once an award ends, if continued funding is desired, a new application must be submitted under an applicable funding opportunity announcement and competitively reviewed. If selected for funding, a new award will be issued. All applications are reviewed for technical merit and relevance to the mission of the USAMRDC and its programs. Also, additional specific evaluation criteria will be included in each funding opportunity announcement. Grant and cooperative agreement awards provide funds to develop science and technology capabilities in specific areas of interest identified in each funding opportunity announcement. Notices of funding opportunity may be called Broad Agency Announcements or Program Announcements. Recipients must strictly conform to all applicable Federal, Department of Defense (DoD), Defense Health Agency (DHA), and U.S. Army Medical Research and Development Command (USAMRDC) requirements for conducting research, including regulatory requirements involving human subjects, human anatomical substances, human cadavers, and animals. Not applicable. Not applicable. Generally, a recipient is required to retain records relating to a particular award for three years from the date of submission of the final financial report. In cases where litigation, claim or an audit is initiated prior to expiration of the three-year period, records must be retained until the action and resolution of any issues associated with it are complete or until the end of the three-year retention period, whichever is later. Records for real property and equipment acquired with Federal funds must be retained for three years after final disposition. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. The maximum period acceptable for a research project is specified in each notice of funding opportunity. However, the maximum initial period of performance for any award is five years. The length of time for which support is requested should be consistent with the nature and complexity of the proposed research. Depending on the source of funding, some awards will be fully funded at the time of award, while others will be incrementally funded. Payments will be made by advance and reimbursement methods. None/Not specified. Ms. Jennifer Cramer
U.S. Army Medical Research Acquisition Activity, Attn: FCMR-ABB-GE
Fort Detrick, MD 21702-5014 US
jennifer.l.cramer9.civ@health.mil
Phone: (301) 619-7145 https://usamraa.health.mil/Pages/Main01.aspx 97-0130-0-1-051 (Project Grants (Discretionary)) FY 22$1,276,429,930.00; FY 23 est $1,275,000,000.00; FY 24 est $1,225,000,000.00; FY 21$1,222,676,775.00; FY 20$1,262,733,178.00; FY 19$1,192,407,886.00; FY 18$993,269,424.00; FY 17$974,976,076.00; FY 16$1,072,663,605.00; - This Assistance Listing supports approximately 30 or more programs each year. Overall, awards are expected to range from $100,000 to $20M (consortium) depending on the funding priorities, anticipated number of awards, and project activity/scope within each program for an award period, on average, of 3 to 4 years. The maximum award amount, if any, is specified in each Program Announcement or Broad Agency Announcement. Notices of funding opportunity are available at Grants.gov by searching Assistance Listing Number 12.420 on the "Search Grants" tab. Applicable requirements in the DoD Grant and Agreement Regulations (DoDGARs) found in Chapter I, Subchapter C of Title 32, Code of Federal Regulations (CFR) and Chapter XI of Title 2, CFR apply to grants and cooperative agreements resulting from this Assistance Listing. Fiscal Year 2017 No Current Data Available.
Fiscal Year 2018 Gulf War Illness Research Program
Fiscal Year 2020 Traumatic Brain Injury Research Program
Fiscal Year 2021 Hearing Restoration Research Program
Fiscal Year 2022 Combat Readiness-Medical Research Program
Fiscal Year 2023 Spinal Cord Injury Research Program